A clinical study of bevacizumab to analyze a correlation of efficacy and the VEGF-related gene cluster for Patients with Advanced Non- Squamous Non-Small Cell Lung Cancer -KTOSG1003-

A clinical study of bevacizumab to analyze a correlation of efficacy and the VEGF-related gene cluster for Patients with Advanced Non- Squamous Non-Small Cell Lung Cancer -KTOSG1003- - KTOSG1003 study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007630

Enrollment

Registered

2012-03-31

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

Bevacizumab treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Writtened informed consent (2)Age of 20 years or older (3)Performance Status (ECOG) 0-1. (4)Life expectancy of at least 3 months (5)Histologically or cytrologically confirmed diagnosis of NSCLC without squamus cell carcinoma (6)Tumors must have measurable disease by RECIST ver1.1. (7)adequate organ function.

Exclusion criteria

Exclusion criteria: (1)CNS metastasis. (2)History of treatment for brain metastasis. (3)History of active double cancer. (4)History of hemoptysis or hemosputum. (5)Evidence of bleeding diathesis or coagulopathy. (6)With great vessel invasion or cavity in tumor. (7)Radiotherapy for thoracic lesions. (8)History of severe heart disease. (9)Superior vena cava syndrome. (10)Spinal cord compression (11)Current or previous history (within the last 1 year) of symptomatic cerebrovascular disease. (12)Non-healing bone fracture and wound. (13)Active infectious disease in need of intravenous administration of anti-bacterial, anti-fungal, or anti-viral drugs. (14)Plan of the operation. (15)Uncontrollable thrombosis. (16)Uncontrollable gastrointestinal ulceration. (17)Current or previous(within the last 1 year)history of GI perforation. (18)Uncontrollable systemic disease (hyper tension or diabetes mellitus). (19)Severe cardiac disease. (20)Interstitial pneumonia or pulmonary fibrosis detectable on X-ray. (21)Peripheral neuropathy > Grade2. (22)With a history of drug sensitivity. (23)History of bevacizumab treatment in the past. (24)History of pregnancy or lactation. (25)No intention to practice birth control. (26)Registration to other trial. (27)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.

Design outcomes

Primary

Measure	Time frame
Explore the positive predictive biomarkers of bevacizumab	—

Secondary

Measure	Time frame
Response rate, Prgression free survival, safety	—

Countries

Japan

Contacts

Public ContactSho Saeki

Kumamoto University Hospital Department of Respiratory Medicine

saeshow@wg7.so-net.ne.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026